306 related articles for article (PubMed ID: 15834456)
1. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine.
Ley LM; Becker A; Lühmann R; Sander P; Lücker PW
Methods Find Exp Clin Pharmacol; 2005; 27(1):25-9. PubMed ID: 15834456
[TBL] [Abstract][Full Text] [Related]
2. The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery.
Memiş D; Turan A; Karamanlioglu B; Saral P; Türe M; Pamukçu Z
Anesth Analg; 2003 Nov; 97(5):1360-1363. PubMed ID: 14570652
[TBL] [Abstract][Full Text] [Related]
3. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
5. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
6. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole.
Hartmann M; Ehrlich A; Fuder H; Lühmann R; Emeklibas S; Timmer W; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1998 Oct; 12(10):1027-32. PubMed ID: 9798809
[TBL] [Abstract][Full Text] [Related]
7. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
Jensen DM; Pace SC; Soffer E; Comer GM;
Am J Gastroenterol; 2006 Sep; 101(9):1991-9; quiz 2170. PubMed ID: 16968504
[TBL] [Abstract][Full Text] [Related]
10. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs.
Bersenas AM; Mathews KA; Allen DG; Conlon PD
Am J Vet Res; 2005 Mar; 66(3):425-31. PubMed ID: 15822586
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.
Geus WP; Mathôt RA; Mulder PG; Lamers CB
Aliment Pharmacol Ther; 2000 Aug; 14(8):1057-64. PubMed ID: 10930900
[TBL] [Abstract][Full Text] [Related]
12. Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding.
Huggins RM; Scates AC; Latour JK
Ann Pharmacother; 2003 Mar; 37(3):433-7. PubMed ID: 12639176
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of the third pump inhibitor--pantoprazole--in the short-term treatment of Chinese patients with duodenal ulcer.
Chen TS; Chang FY; Ng WW; Lee FY; Hwang SJ; Lee SD
Hepatogastroenterology; 1999; 46(28):2372-8. PubMed ID: 10522000
[TBL] [Abstract][Full Text] [Related]
14. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
15. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
17. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study.
Schepp W; Classen M
Scand J Gastroenterol; 1995 Jun; 30(6):511-4. PubMed ID: 7569755
[TBL] [Abstract][Full Text] [Related]
18. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
[TBL] [Abstract][Full Text] [Related]
19. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
20. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours.
Netzer P; Gaia C; Sandoz M; Huluk T; Gut A; Halter F; Hüsler J; Inauen W
Am J Gastroenterol; 1999 Feb; 94(2):351-7. PubMed ID: 10022628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
